Supernus Pharmaceuticals (NASDAQ:SUPN) Sets New 12-Month High - Should You Buy?

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) reached a new 52-week high during mid-day trading on Monday . The company traded as high as $39.39 and last traded at $39.25, with a volume of 37092 shares changing hands. The stock had previously closed at $38.55.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on SUPN shares. Piper Sandler reaffirmed a "neutral" rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Cantor Fitzgerald initiated coverage on Supernus Pharmaceuticals in a research note on Monday, January 6th. They issued an "overweight" rating and a $57.00 target price for the company. Finally, Cowen reissued a "buy" rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th.

Supernus Pharmaceuticals Price Performance

The stock has a market capitalization of $2.18 billion, a price-to-earnings ratio of 36.83 and a beta of 0.90. The business has a fifty day moving average of $36.91 and a 200 day moving average of $34.25.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 EPS for the quarter, beating the consensus estimate of $0.44 by $0.25. The business had revenue of $175.70 million for the quarter, compared to analyst estimates of $157.35 million. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. The company's quarterly revenue was up 14.2% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.29) EPS. On average, equities research analysts expect that Supernus Pharmaceuticals, Inc. will post 2.37 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Jack A. Khattar sold 125,000 shares of the firm's stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $36.68, for a total transaction of $4,585,000.00. Following the completion of the transaction, the chief executive officer now directly owns 926,172 shares in the company, valued at $33,971,988.96. This trade represents a 11.89 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Georges Gemayel sold 14,213 shares of Supernus Pharmaceuticals stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $36.62, for a total value of $520,480.06. Following the completion of the transaction, the director now directly owns 13,315 shares of the company's stock, valued at approximately $487,595.30. This represents a 51.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 154,213 shares of company stock valued at $5,660,180 over the last 90 days. 9.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Sei Investments Co. boosted its holdings in Supernus Pharmaceuticals by 2.1% in the second quarter. Sei Investments Co. now owns 337,658 shares of the specialty pharmaceutical company's stock valued at $9,032,000 after purchasing an additional 7,078 shares during the period. ProShare Advisors LLC boosted its stake in shares of Supernus Pharmaceuticals by 59.8% in the 2nd quarter. ProShare Advisors LLC now owns 22,152 shares of the specialty pharmaceutical company's stock valued at $593,000 after buying an additional 8,293 shares during the period. Bank of Montreal Can boosted its stake in shares of Supernus Pharmaceuticals by 1,508.0% in the 2nd quarter. Bank of Montreal Can now owns 116,322 shares of the specialty pharmaceutical company's stock valued at $3,287,000 after buying an additional 109,088 shares during the period. Marshall Wace LLP acquired a new position in shares of Supernus Pharmaceuticals during the second quarter worth about $1,967,000. Finally, Cubist Systematic Strategies LLC increased its stake in shares of Supernus Pharmaceuticals by 98.3% during the second quarter. Cubist Systematic Strategies LLC now owns 79,632 shares of the specialty pharmaceutical company's stock worth $2,130,000 after buying an additional 39,479 shares during the period.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.